Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CERo Therapeutics Holdings Inc CERO

Healthcare Biotechnology
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body’s full immune... see more

Recent & Breaking News (NDAQ:CERO)

    CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

    GlobeNewswire 8 days ago

    CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

    GlobeNewswire 12 days ago

    CERo Therapeutics, Inc. Provides Corporate Update

    GlobeNewswire October 21, 2024

    CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

    GlobeNewswire October 2, 2024

    CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

    GlobeNewswire September 25, 2024

    CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024

    GlobeNewswire July 8, 2024

    CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

    GlobeNewswire June 13, 2024

    CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

    GlobeNewswire June 6, 2024

    CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

    GlobeNewswire May 15, 2024

    CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes

    GlobeNewswire April 30, 2024

    CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

    Business Wire March 7, 2024

    Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination

    Business Wire February 14, 2024

    CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics

    Business Wire June 5, 2023